120 related articles for article (PubMed ID: 27829371)
1. Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma.
Pezzi A; Cavo M; Biggeri A; Zamagni E; Nanni O
BMC Med Res Methodol; 2016 Nov; 16(1):150. PubMed ID: 27829371
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
3. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
5. Improve efficiency and reduce bias of Cox regression models for two-stage randomization designs using auxiliary covariates.
Yang X; Zhou Y
Stat Med; 2017 May; 36(11):1683-1695. PubMed ID: 28183157
[TBL] [Abstract][Full Text] [Related]
6. Adaptive truncated weighting for improving marginal structural model estimation of treatment effects informally censored by subsequent therapy.
Bai X; Liu J; Li L; Faries D
Pharm Stat; 2015; 14(6):448-54. PubMed ID: 26436533
[TBL] [Abstract][Full Text] [Related]
7. Model misspecification and robustness in causal inference: comparing matching with doubly robust estimation.
Waernbaum I
Stat Med; 2012 Jul; 31(15):1572-81. PubMed ID: 22359267
[TBL] [Abstract][Full Text] [Related]
8. Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.
Johnsen HE; Klausen TW; Boegsted M; Lenhoff S; Gimsing P; Christiansen I; Gedde-Dahl T; Lindås R; Mellqvist UH;
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):290-6. PubMed ID: 20709667
[TBL] [Abstract][Full Text] [Related]
9. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
10. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
[TBL] [Abstract][Full Text] [Related]
11. An application of propensity score weighting to quantify the causal effect of rectal sexually transmitted infections on incident HIV among men who have sex with men.
Vaughan AS; Kelley CF; Luisi N; del Rio C; Sullivan PS; Rosenberg ES
BMC Med Res Methodol; 2015 Mar; 15():25. PubMed ID: 25888416
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
13. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
14. Assessing the effect of a partly unobserved, exogenous, binary time-dependent covariate on survival probabilities using generalised pseudo-values.
Pötschger U; Heinzl H; Valsecchi MG; Mittlböck M
BMC Med Res Methodol; 2018 Jan; 18(1):14. PubMed ID: 29351735
[TBL] [Abstract][Full Text] [Related]
15. Propensity score methods for estimating relative risks in cluster randomized trials with low-incidence binary outcomes and selection bias.
Leyrat C; Caille A; Donner A; Giraudeau B
Stat Med; 2014 Sep; 33(20):3556-75. PubMed ID: 24771662
[TBL] [Abstract][Full Text] [Related]
16. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
17. Combining propensity score-based stratification and weighting to improve causal inference in the evaluation of health care interventions.
Linden A
J Eval Clin Pract; 2014 Dec; 20(6):1065-71. PubMed ID: 25266868
[TBL] [Abstract][Full Text] [Related]
18. Why caution is recommended with post-hoc individual patient matching for estimation of treatment effect in parallel-group randomized controlled trials: the case of acute stroke trials.
Jafari N; Hearne J; Churilov L
Stat Med; 2013 Nov; 32(25):4467-81. PubMed ID: 23761106
[TBL] [Abstract][Full Text] [Related]
19. Causal effect estimation strategies in a longitudinal study with complex time-varying confounders: A tutorial.
Mertens BJ; Datta S; Brand R; Peul W
Stat Methods Med Res; 2017 Feb; 26(1):337-355. PubMed ID: 25147227
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
